Phonosurgical Augmentation After Laser Resection of Early Glottic Carcinoma
Status:
Completed
Trial end date:
2018-08-13
Target enrollment:
Participant gender:
Summary
Objectives: Transoral Laser Microsurgery (TLM) is widely used in for treating T1/T2 glottic
cancers. Hyaluronic acid (HA) is a safe and commonly-used injectable in vocal cord
augmentation. We report on the results of our single-blinded, randomized-controlled trial
(RCT) investigating the impact of intra-operative HA injection on voice outcomes in early
glottic cancer.
Methods: Patients with T1/T2 glottic cancers were randomized to the treatment group (n=14)
receiving HA injection to the unaffected cord during TLM; or the control group, receiving no
injection (n=16). All patients had a Voice Handicap Index-10 (VHI-10) questionnaire and a
Maximum Phonation Time (MPT) measurement preoperatively and at 3, 12 and 24 months
post-operatively. Mean change in VHI-10 and MPT, between pre-operative and post-operative
time points, and between the time points, were compared. Survival estimates were also
calculated.